Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2018

Open Access 01-12-2018 | Primary research

Psychopathology of addiction: Can the SCL90-based five-dimensional structure differentiate Heroin Use Disorder from a non-substance-related addictive disorder such as Gambling Disorder?

Authors: Angelo G. I. Maremmani, Denise Gazzarrini, Amelia Fiorin, Valeria Cingano, Graziano Bellio, Giulio Perugi, Icro Maremmani

Published in: Annals of General Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

In the Gambling Disorder (GD), there is no exogenous drug administration that acts as the central core of the traditional meaning of addiction. A specific psychopathology of Substance Use Disorders has been proposed recently. In a sample of Heroin Use Disorder (HUD) patients entering opioid agonist treatment, it became possible to identify a group of 5 mutually exclusive psychiatric dimensions: Worthlessness-Being trapped (W-BT), Somatic Symptoms (SS), Sensitivity-Psychoticism (SP), Panic Anxiety (PA) and Violence-Suicide (VS). The specificity of these dimensions was suggested by the absence of their correlations with treatment choice, active substance use, psychiatric comorbidity and the principal substance of abuse and by the opportunity, through their use, of fully discriminating HUD from Major Depression patients and, partially, from obese non-psychiatric patients. To further support this specificity in the present study, we tested the feasibility of discriminating HUD patients from those affected by a non-substance-related addictive behaviour, such as GD. In this way, we also investigated the psychopathological peculiarities of GD patients.

Methods

We compared the severity and frequency of each of the five aspects found by us, in 972 (83.5% males; mean age 30.12 ± 6.6) HUD and 110 (50% males; average age 30.12 ± 6.6) GD patients at univariate (T test; Chi square) and multivariate (discriminant analysis and logistic regression) level.

Results

HUD patients showed higher general psychopathology indexes than GD patients. The severity of all five psychopathological dimensions was significantly greater in HUD patients. Discriminant analysis revealed that SS and VS severity were able to discriminate between HUD (higher severity) and GD patients (lower severity), whereas PA and SP could not. W-BT severity was negatively correlated with SS and VS; GD patients were distinguished by low scores for SS and VS low scores associated with high ones for W-BT. Psychopathological subtypes characterized by SS and VS symptomatology were better represented in HUD patients, whereas PA symptomatology was more frequent in GD individuals. No differences were observed regarding the W-BT and SP dimensions. At multivariate level, the one prominent characteristic of HUD patients was the presence of SS (OR = 5.43) as a prominent qualification for psychopathological status.

Conclusions

Apart from the lower severity of all psychopathological dimensions, only the lower frequency of SS typology seems to be the prominent factor in GD patients. The SCL90-defined structure of opioid addiction seems to be useful even in non-substance-related addictive disorders, as in the case of GD patients, further supporting the possible existence of a psychopathology specific to addiction.
Literature
1.
Rash CJ, Petry NM. Gambling Disorder in the DSM-5: opportunities to improve diagnosis and treatment especially in substance use and homeless populations. Curr Addict Rep. 2016;3(3):249–53.CrossRefPubMedPubMedCentral
2.
3.
4.
Schuckit MA. Editor’s corner: DSM-5–ready or not, here it comes. J Stud Alcohol Drugs. 2013;74(5):661–3.CrossRefPubMed
5.
Kyngdon A, Dickerson M. An experimental study of the effect of prior alcohol consumption on a simulated gambling activity. Addiction. 1999;94(5):697–707.CrossRefPubMed
6.
Nower L, Blaszczynski A. Recovery in pathological gambling: an imprecise concept. Subst Use Misuse. 2008;43(12–13):1844–64.CrossRefPubMed
7.
de Castro V, Fong T, Rosenthal RJ, Tavares H. A comparison of craving and emotional states between pathological gamblers and alcoholics. Addict Behav. 2007;32(8):1555–64.CrossRefPubMed
8.
Griffiths M. Tolerance in gambling: an objective measure using the psychophysiological analysis of male fruit machine gamblers. Addict Behav. 1993;18(3):365–72.CrossRefPubMed
9.
Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res. 2000;126:325–41.CrossRefPubMed
10.
Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247–91.CrossRefPubMed
11.
12.
Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12(11):652–69.CrossRefPubMedPubMedCentral
13.
Hommer DW, Bjork JM, Gilman JM. Imaging brain response to reward in addictive disorders. Ann N Y Acad Sci. 2011;1216:50–61.CrossRefPubMed
14.
Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005;8(2):147–8.CrossRefPubMed
15.
Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry. 2004;16(1):27–34.CrossRefPubMed
16.
Lawrence AJ, Luty J, Bogdan NA, Sahakian BJ, Clark L. Impulsivity and response inhibition in alcohol dependence and problem gambling. Psychopharmacology. 2009;207(1):163–72.CrossRefPubMedPubMedCentral
17.
Leeman RF, Potenza MN. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology. 2012;219(2):469–90.CrossRefPubMed
18.
Blaszczynski A, Steel Z, McConaghy N. Impulsivity in pathological gambling: the antisocial impulsivist. Addiction. 1997;92(1):75–87.CrossRefPubMed
19.
Petry NM. Substance abuse, pathological gambling, and impulsiveness. Drug Alcohol Depend. 2001;63(1):29–38.CrossRefPubMed
20.
Potenza MN, Steinberg MA, Skudlarski P, Fulbright RK, Lacadie CM, Wilber MK, Rounsaville BJ, Gore JC, Wexler BE. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60(8):828–36.CrossRefPubMed
21.
Cavedini P, Riboldi G, Keller R, D’Annucci A, Bellodi L. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry. 2002;51(4):334–41.CrossRefPubMed
22.
Zhou Y, Proudnikov D, Yuferov V, Kreek MJ. Drug-induced and genetic alterations in stress-responsive systems: implications for specific addictive diseases. Brain Res. 2010;1314:235–52.CrossRefPubMed
23.
el-Guebaly N, Mudry T, Zohar J, Tavares H, Potenza MN. Compulsive features in behavioural addictions: the case of pathological gambling. Addiction. 2012;107(10):1726–34.CrossRefPubMed
24.
Black DW, Moyer T, Schlosser S. Quality of life and family history in pathological gambling. J Nerv Ment Dis. 2003;191(2):124–6.PubMed
25.
Lobo DS, Kennedy JL. Genetic aspects of pathological gambling: a complex disorder with shared genetic vulnerabilities. Addiction. 2009;104(9):1454–65.CrossRefPubMed
26.
Rennert L, Denis C, Peer K, Lynch KG, Gelernter J, Kranzler HR. DSM-5 gambling disorder: prevalence and characteristics in a substance use disorder sample. Exp Clin Psychopharmacol. 2014;22(1):50–6.CrossRefPubMedPubMedCentral
27.
Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(Suppl 1):142–51.CrossRefPubMed
28.
Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction. 2011;106(3):490–8.CrossRefPubMed
29.
Cowlishaw S, Merkouris S, Chapman A, Radermacher H. Pathological and problem gambling in substance use treatment: a systematic review and meta-analysis. J Subst Abuse Treat. 2014;46(2):98–105.CrossRefPubMed
30.
Rash CJ, Weinstock J, Petry NM. Drinking patterns of pathological gamblers before, during, and after gambling treatment. Psychol Addict Behav. 2011;25(4):664–74.CrossRefPubMedPubMedCentral
31.
Hodgins DC, el-Guebaly N. The influence of substance dependence and mood disorders on outcome from pathological gambling: 5-year follow-up. J Gambl Stud. 2010;26(1):117–27.CrossRefPubMed
32.
Kessler RC, Hwang I, LaBrie R, Petukhova M, Sampson NA, Winters KC, Shaffer HJ. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med. 2008;38(9):1351–60.CrossRefPubMedPubMedCentral
33.
Bergh C, Kuhlhorn E. Social, psychological and physical consequences of pathological gambling in Sweden. J Gambl Stud. 1994;10(3):275–85.CrossRefPubMed
34.
McCormick RA, Russo AM, Ramirez LF, Taber JI. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry. 1984;141(2):215–8.CrossRefPubMed
35.
Dowling NA, Cowlishaw S, Jackson AC, Merkouris SS, Francis KL, Christensen DR. Prevalence of psychiatric co-morbidity in treatment-seeking problem gamblers: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2015;49(6):519–39.CrossRefPubMedPubMedCentral
36.
Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(5):564–74.CrossRefPubMed
37.
Maremmani I, Pani PP, Pacini M, Bizzarri JV, Trogu E, Maremmani AGI, Perugi G, Gerra G, Dell’Osso L. Subtyping Patients with Heroin Addiction at treatment entry: factors derived from the SCL-90. Ann Gen Psychiatry. 2010;9(1):15.CrossRefPubMedPubMedCentral
38.
Pani PP, Maremmani AGI, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U, Amato L, Ghibaudi J, Camposeragna A, et al. Psychopathology of addiction: May a SCL-90 based five dimensions structure be applied irrespectively of the involved drug? Ann Gen Psychiatry. 2016;15:13.CrossRefPubMedPubMedCentral
39.
Pani PP, Maremmani AGI, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U, Amato L, Davoli M, Ghibaudi J, et al. Psychic structure of opioid addiction: impact of lifetime psychiatric problems on SCL-90-based psychopathologic dimensions in heroin-dependent patients. Addict Disord Treat. 2016;15(1):6–16.CrossRef
40.
Pani PP, Maremmani AGI, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U, Amato L, Davoli M, Ghibaudi J, et al. Psychopathological symptoms in detoxified and non-detoxified heroin-dependent patients entering residential treatment. Heroin Addict Relat Clin Probl. 2015;17(2–3):17–24.
41.
Pani PP, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U, Amato L, Davoli M, Ghibaudi J, Camposeragna A, et al. Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment. Ann Gen Psychiatry. 2014;13(1):35.CrossRefPubMedPubMedCentral
42.
Maremmani I, Pacini M, Lubrano S, Perugi G, Tagliamonte A, Pani PP, Gerra G, Shinderman M. Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis). Eur Addict Res. 2008;14(3):134–42.CrossRefPubMed
43.
Maremmani AGI, Pani PP, Trogu E, Vigna-Taglianti F, Mathis F, Diecidue R, Kirchmayer U, Amato L, Ghibaudi J, Composeragna A, et al. The impact of psychopathological subtypes on retention rate of patients with substance use disorders entering residential therapeutic community treatment. Ann Gen Psychiatry. 2016;15(1):29.CrossRefPubMedPubMedCentral
44.
Maremmani AGI, Cerniglia L, Cimino S, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D, Pallucchini A, Pani PP, et al. Towards a specific psychopathology of heroin addiction. Comparison between Heroin Use Disorder and Major Depression patients. Heroin Addict Relat Clin Probl. 2015;17(6):9–16.
45.
Maremmani AGI, Cerniglia L, Cimino S, Bacciardi S, Rovai L, Pallucchini A, Spera V, Perugi G, Maremmani I. Further evidence of a specific psychopathology of addiction. Differentiation from other psychiatric psychopathological dimensions (such as obesity). Int J Environ Res Public Health. 2017;14(8):943.CrossRefPubMedCentral
46.
Derogatis LR, Lipman RS, Rickels K. The Hopkins Symptom Checklist (HSCL)—A self report symptom inventory. Behav Sci. 1974;19:1–16.CrossRefPubMed
47.
Maremmani AGI, Rovai L, Maremmani I. Heroin addicts’ psychopathological subtypes. Correlations with the natural history of illness. Heroin Addict Relat Clin Probl. 2012;14(1):11–22.
48.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I disorders (SCID-I), Clinician Version. Arlington: American Psychiatric Publishing, Inc; 1997.
49.
Blaszczynski AP, McConaghy N. SCL-90 assessed psychopathology in pathological gamblers. Psychol Rep. 1988;62(2):547–52.CrossRefPubMed
50.
Jimenez-Murcia S, Del Pino-Gutierrez A, Fernandez-Aranda F, Granero R, Hakansson A, Tarrega S, Valdeperez A, Aymami N, Gomez-Pena M, Moragas L, et al. Treatment outcome in male Gambling Disorder patients associated with alcohol use. Front Psychol. 2016;7:465.CrossRefPubMedPubMedCentral
51.
Gonzalez-Ibanez A, Aymami MN, Jimenez S, Domenech JM, Granero R, Lourido-Ferreira MR. Assessment of pathological gamblers who use slot machines. Psychol Rep. 2003;93(3 Pt 1):707–16.CrossRefPubMed
52.
Gonzalez-Ibanez A, Mora M, Gutierrez-Maldonado J, Ariza A, Lourido-Ferreira MR. Pathological gambling and age: differences in personality, psychopathology, and response to treatment variables. Addict Behav. 2005;30(2):383–8.CrossRefPubMed
53.
Jimenez-Murcia S, Alvarez-Moya EM, Stinchfield R, Fernandez-Aranda F, Granero R, Aymami N, Gomez-Pena M, Jaurrieta N, Bove F, Menchon JM. Age of onset in pathological gambling: clinical, therapeutic and personality correlates. J Gambl Stud. 2010;26(2):235–48.CrossRefPubMed
54.
Bonnaire C, Kovess-Masfety V, Guignard R, Richard JB, du Roscoat E, Beck F. Gambling type, substance abuse, health and psychosocial correlates of male and female problem gamblers in a nationally representative French Sample. J Gambl Stud 2017;33(2):343–69.CrossRefPubMed
55.
Castren S, Salonen AH, Alho H, Lahti T, Simojoki K. Past-year gambling behaviour among patients receiving opioid substitution treatment. Subst Abuse Treat Prev Policy. 2015;10:4.CrossRefPubMedPubMedCentral
56.
Peles E, Schreiber S, Adelson M. Pathological gambling and obsessive compulsive disorder among methadone maintenance treatment patients. J Addict Dis. 2009;28(3):199–207.CrossRefPubMed
57.
Peles E, Schreiber S, Linzy S, Adelson M. Pathological gambling in methadone maintenance clinics where gambling is legal versus illegal. Am J Orthopsychiatry. 2010;80(3):311–6.CrossRefPubMed
58.
59.
Toneatto T, Brennan J. Pathological gambling in treatment-seeking substance abusers. Addict Behav. 2002;27(3):465–9.CrossRefPubMed
60.
Weinstock J, Blanco C, Petry NM. Health correlates of pathological gambling in a methadone maintenance clinic. Exp Clin Psychopharmacol. 2006;14(1):87–93.CrossRefPubMed
Metadata
Title
Psychopathology of addiction: Can the SCL90-based five-dimensional structure differentiate Heroin Use Disorder from a non-substance-related addictive disorder such as Gambling Disorder?
Authors
Angelo G. I. Maremmani
Denise Gazzarrini
Amelia Fiorin
Valeria Cingano
Graziano Bellio
Giulio Perugi
Icro Maremmani
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2018
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-018-0173-7

Other articles of this Issue 1/2018

Annals of General Psychiatry 1/2018 Go to the issue

Primary research

Prevalence and associated factors of depression among patients with HIV/AIDS in Hawassa, Ethiopia, cross-sectional study

Primary research

The long-term outcome of patients with heroin use disorder/dual disorder (chronic psychosis) after admission to enhanced methadone maintenance

Case report

Parent–Child Interaction Therapy (PCIT) for young children with Attention-Deficit Hyperactivity Disorder (ADHD) in Japan

Primary research

Suicidal thoughts among university students in Ethiopia

Primary research

Amygdala functional connectivity in female patients with major depressive disorder with and without suicidal ideation

Primary research

Chewing khat and risky sexual behavior among residents of Bahir Dar City administration, Northwest Ethiopia